Ganoderic acid H
Based on 1 Customer Validation
Ganoderic acid H is a hydroxylated lanostane-type triterpenoid derived from Ganoderma lucidum with anticancer activity. Ganoderic acid H inhibits the constitutive transactivation activity of AP-1 and NF-κB; it also downregulates the secretion of uPA and the expression of CDK4, and suppresses the growth, adhesion, migration and invasion of cancer cells. Ganoderic acid H inhibits HIV-1 protease in vitro. Ganoderic acid H can be used in studies related to breast cancer and HIV infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.68%
- CAS No.: 98665-19-1
- Formule: C32H44O9
- Masse moléculaire:572.69
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform AP-1
More
Activité biologique
Description
IC50 & Target
[1]|
CDK4 |
NF-κB |
In Vitro
Ganoderic acid H (0.10-0.50 mM; 14 days) inhibits the anchorage-independent growth (colony formation) of human breast cancer MDA-MB-231 cells in a dose-dependent manner over a 14-day incubation period[1].
Ganoderic acid H (0.10-0.50 mM; 24 h) dose-dependently inhibits the adhesion of human breast cancer cell line MDA-MB-231 to vitronectin[1].
Ganoderic acid H (0.10-0.50 mM; 5 h) inhibits the migration of human breast cancer MDA-MB-231 cells in a dose-dependent manner[1].
Ganoderic acid H (0.10-0.50 mM; 24 h pretreatment) dose-dependently inhibits the Matrigel invasion ability of human breast cancer cell line MDA-MB-231; it dose-dependently suppresses the constitutive transactivation activity of AP-1 and NF-κB without altering their DNA-binding activity; and it dose-dependently downregulates uPA secretion and CDK4 protein expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.10, 0.25, 0.50 mM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Inhibited the growth of MDA-MB-231 cells in a time- and dose-dependent manner.
Reduced cell growth by 38.3% at 0.50 mM after 24 h incubation.
Reduced cell growth by 48.3% at 0.50 mM after 48 h incubation.
Reduced cell growth by 57.7% at 0.50 mM after 72 h incubation.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.10, 0.25, 0.50 mM
-
Incubation Time:5 h
-
Result:Reduced the migration rate of MDA-MB-231 cells in a dose-dependent manner.
Decreased migration to 71.3% of control levels at 0.10 mM after 5 h incubation.
Decreased migration to 48.1% of control levels at 0.25 mM after 5 h incubation.
Decreased migration to 35.6% of control levels at 0.50 mM after 5 h incubation.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.10, 0.25, 0.50 mM
-
Incubation Time:24 h pretreatment, followed by 24 h invasion incubation
-
Result:Inhibited the invasion of MDA-MB-231 cells in a dose-dependent manner.
Reduced invasion to 56.9% of control levels at 0.10 mM after 24 h pretreatment.
Reduced invasion to 46.3% of control levels at 0.25 mM after 24 h pretreatment.
Reduced invasion to 15.5% of control levels at 0.50 mM after 24 h pretreatment.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.10, 0.25, 0.50 mM
-
Incubation Time:14 days
-
Result:Inhibited the anchorage-independent growth (colony formation) of human breast cancer MDA-MB-231 cells in a dose-dependent manner over a 14-day incubation period.
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.10, 0.25, 0.50 mM
-
Incubation Time:24 h
-
Result:Markedly reduced the secretion of uPA from MDA-MB-231 cells in a dose-dependent manner.\nMarkedly decreased the expression of Cdk4 protein in MDA-MB-231 cells in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 98665-19-1
-
Appearance Solid
-
Masse moléculaire 572.69
-
Formule C32H44O9
-
Color Off-white to light yellow
-
SMILES
CC(C)(C1C2)C(O)CCC1(C)C3=C(C4(C(CC(C4(C(OC(C)=O)C3=O)C)C(C)CC(CC(C)C(O)=O)=O)=O)C)C2=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (174.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (295 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7461 mL | 8.7307 mL | 17.4615 mL | 43.6536 mL |
| 5 mM | 0.3492 mL | 1.7461 mL | 3.4923 mL | 8.7307 mL | |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7461 mL | 4.3654 mL | |
| 15 mM | 0.1164 mL | 0.5820 mL | 1.1641 mL | 2.9102 mL | |
| 20 mM | 0.0873 mL | 0.4365 mL | 0.8731 mL | 2.1827 mL | |
| 25 mM | 0.0698 mL | 0.3492 mL | 0.6985 mL | 1.7461 mL | |
| 30 mM | 0.0582 mL | 0.2910 mL | 0.5820 mL | 1.4551 mL | |
| 40 mM | 0.0437 mL | 0.2183 mL | 0.4365 mL | 1.0913 mL | |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.8731 mL | |
| 60 mM | 0.0291 mL | 0.1455 mL | 0.2910 mL | 0.7276 mL | |
| 80 mM | 0.0218 mL | 0.1091 mL | 0.2183 mL | 0.5457 mL | |
| 100 mM | 0.0175 mL | 0.0873 mL | 0.1746 mL | 0.4365 mL |
Ganoderic acid H Related Classifications
HY-N1513 Related Classifications
Powered by Bioz